RECENT ADVANCES IN RENAL TRANSPLANT BY PERSONALIZING IMMUNOSUPPRESSIVE THERAPIES
Economic evaluation of the personalisation of immunosuppressive therapy in kidney
transplantation by means of an in vitro diagnostic test (Immunobiogram®) in Spain
Economic impact of the Immunobiogram
Carlos Jiménez Martín, José María Portolés, Marta Crespo. Carlos Rubio-Terrés, Darío Rubio-Rodríguez, Teresa Díez, Isabel Portero Sánchez.
“Economic evaluation of the personalization of immunosuppressive therapy in kidney transplantation by means of an in vitro diagnostic test (Immunobiogram®) in Spain”. Rev Esp Eco Salud 2022; 17(1):23-34
Key findings in the paper are:
The use of the IMBG would entail a:
-
- potential risk reduction of graft failure, with costs savings of €20,263 (95% CI €17,520-23,678) per high-risk transplanted patient in 5 years ) (100% saving probability).
- potential reduction in the AE rate that would generate savings per non-high-risk patient in 5 years of € 1,409 (95% CI € 41-3,316) (97.8% saving probability).
- Compared with the option of not using IMBG, a potential gain of 0.5256 (95% CI 0.3388 – 0.7452) years of life and 0.0219 (95% CI 0.0115 – 0.0356) quality-adjusted life years (QALY) in each patient evaluated with IMBG.
Frontiers in Immunology
A paper about the Immunobiogram technology
José María Portolés, Carlos Jiménez, Darío Janeiro, María O. López-Oliva, Álvaro Ortega- Carrión, Daniel Blanquez, Luis Arribas, Carlos Gómez, Teresa Diez, Julio Pascual e Isabel Portero.
“The Immunobiogram, a Novel In Vitro Assay to Evaluate Treatment Resistance in Patients Receiving Immunosuppressive Therapy”
Frontiers in immunology 2021; 11: 3483. DOI=10.3389/fimmu.2020.618202
Key findings in the paper are:
- Not all patients respond equally to a given immunosuppressant drug. This is due to individual differences in pharmacokinetic and pharmacodynamic responses to drugs
- The IMBG test allows quantification of each patient’s sensitivity to their prescribed immunosuppressant medication. Furthermore, we observed an association between patient treatment results and the immunological risk of rejection of the corresponding patient
- Patients with a greater risk of rejection showed reduced sensitivity to their prescribed immunosuppressant, while those with the lowest risk of rejection showed greater sensitivity to their prescribed medication.
- The IMBG assay thus provides pharmacodynamic information linked to the final efficacy of the patient’s prescribed immunosuppressant(s), which influences their risk of rejection
28th International Congress of the Transplantation Society
Virtual TTS 2020 (13-16 September)
ePoster
Julio Pascual, Carlos Jiménez, Magdalena Krajewska, Daniel Seron, Camille Kotton, Jose María Portolés, Oliver Witzke, Soren Sorensen, Amado Andrés, Teresa Diez , Álvaro Ortega, Isabel Portero.
“Analysis of Immunobiogram pharmacodynamic dose-response curves to immunosuppressants in kidney transplant recipients: further results from Transbio Study Abstract #604.”
Sociedad Española de Trasplantes 2021
SET 2021 6º Congreso 12-14 Febrero (virtual)
ePoster
Julio Pascual1, Carlos Jiménez2, Daniel Seron3, Jose María Portolés4, Amado Andrés5, Teresa Díez6, Alvaro Ortega6 e Isabel Portero6 en representación del TRANSBIO Study group.
” Inmunobiograma, un nuevo inmunoensayo de diagnóstico in-vitro para facilitar el ajuste individualizado del tratamiento inmunosupresor en trasplante renal: Estudio TRANSBIO.”
American Transplantation Congress
ATC 2020 30 May -3th June 2020, Philadelphia
ePoster
Rubio C, Jiménez C, Crespo M, Portolés J, Rubio D, Diez T, Portero I.
Oral abstract presentation
Pascual J, Jiménez C, Krajewska M, Kotton C, Seron D, Portolés J, Witzke O, Sorensen SS, Andrés A, Díez T, Ortega A, Portero I.
Congreso Sociedad Madrileña de Trasplantes
CSMT 2019 (20 al 22 de noviembre, Madrid)
International Society for Pharmacoeconomics and
Outcomes Research
ISPOR Europa 2019 (2-6 November 2019, Copenhagen)
ESOT 2019 (September, Copenhagen)
European Society of Organ Transplantation
Poster:
Julio Pascual, Carlos Jiménez, Magdalena Krajewska, Camile Kotton, Daniel Seron, Jose María Portolés, Oliver Witzke, Soren S Sorensen, Amado Andrés, Teresa Díez, Álvaro Ortega, Isabel Portero on behalf of TRANSBIO Study group.
“Analytical robustness and clinical consistency evaluation of a new in vitro diagnostic BIOtechnological immunoassay to help decision-making in adjustment of immunosuppressant therapy for kidney TRANSplantation”.
American Transplantation Congress
ATC 2019 (1-5 June 2019, Boston)
Poster:
Carlos Jiménez, Jose María Portoles, Daniel Blánquez, Luis Arribas, Álvaro Ortega, Teresa Díez, Isabel Portero on behalf of TRANSBIO STUDY GROUP.
“Immunobiogram, A New IVD Immunoassay To Test The Sensitivity Profile Of Kidney Transplant Recipients To Immunosuppressive Drugs: Further Results From BH-pilot Study”.
Basic Science Transplantation Congress
BST 2018 (11-13 October 2018, Rotterdam)
Poster
Di Scala Marianna, Portolés José Maria, Jiménez Carlos, Janeiro Dario, González Elena, Sánchez Sobrino Beatriz, López Oliva María, Richter Jose, Ortega Álvaro, Pascual Julio, Portero Isabel.
“Immunobiogram: a new immunological tool to personalize immunosuppressive therapy in kidney transplant recipients”
5th European Congress of Immunology 2018
ECI 2018 (2-5th September, Amsterdam)
Workshop (Oral presentation): Di Scala, J. Portolés, C. Jiménez, D. Janeiro , E. González , B. Sánchez Sobrino , M. López Oliva, J. Richter , A. Ortega, J. Pascual , I. Portero.
“ IMMUNOBIOGRAM a new immunological tool to personalize immunosuppressive therapy in kidney transplant recipients.”
Poster: Á. Ortega, M. Di Scala, T. Yebra, T. Diez, J. Richter, I. Portero.
“BIOHOPE Scientific SL, Madrid, Spain “Immunobiogram as a diagnostic assay for detection of resistance to immunomodulatory treatment in patients with chronic inflammatory diseases”.
27th International Congress of the Transplantation Society
TTS 2018 (1-5th July, Madrid)
